References:
1. Khamees I, Ata F, Choudry H, Soliman AT, De Sanctis V, Yassin MA.
Manifestations of HbSE sickle cell disease: a systematic review. J
Transl Med [Internet]. 2021 Dec 1 [cited 2023 Jan
30];19(1):1–10. Available from:
https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-021-02931-1
2. Yassin M, Soliman A, De Sanctis V, Nashwan A, Abusamaan S, Moustafa
A, et al. Liver Iron Content (LIC) in Adults with Sickle Cell Disease
(SCD): Correlation with Serum Ferritin and Liver Enzymes Concentrations
in Trasfusion Dependent (TD-SCD) and Non-Transfusion Dependent (NT-SCD)
Patients. Mediterr J Hematol Infect Dis [Internet]. 2017 [cited
2023 Jan 30];9(1). Available from:
https://pubmed.ncbi.nlm.nih.gov/28698780/
3. Rozi W, Rahhal A, Ali EA, Al-Mashdali A, Hilan Y, Khamees I, et al.
Direct oral anticoagulants in sickle cell disease: a systematic review
and meta-analysis. Blood Adv [Internet]. 2022 Sep 13 [cited 2023
Feb 5];6(17):5061–6. Available from:
https://pubmed.ncbi.nlm.nih.gov/35728061/
4. Elenga N, Loko G, Etienne-Julan M, Al-Okka R, Adel AM, Yassin MA.
Real-World data on efficacy of L-glutamine in preventing sickle cell
disease-related complications in pediatric and adult patients. Front
Med. 2022 Aug 1;9:2233.
5. Ali E, Soliman A, De Sanctis V, Nussbaumer D, Yassin MA. Priapism in
Patients with Chronic Myeloid Leukemia (CML): A Systematic Review. Acta
Bio Medica Atenei Parm [Internet]. 2021 Jul 1 [cited 2023 Feb
5];92(3). Available from: /pmc/articles/PMC8343736/
6. Ataga KI, Kutlar A, Kanter J, Liles D, Cancado R, Friedrisch J, et
al. Crizanlizumab for the Prevention of Pain Crises in Sickle Cell
Disease. N Engl J Med [Internet]. 2017 Feb 2 [cited 2023 Feb
5];376(5):429–39. Available from:
https://www.nejm.org/doi/full/10.1056/NEJMoa1611770
7. Alshurafa A, Yassin MA. Short- and long-term follow-up and additional
benefits in a sickle cell disease patient experienced severe
crizanlizumab infusion-related
vaso-occlusive crisis: A case report. Front Med. 2022 Nov 29;9:3431.
12. Kanter J, Shah A, Joshi V, Mehta H, Levine M, Arunagiri U, et al.
Rare Cases of Infusion-Related Reactions (IRRs) Presenting As Pain
Events during or after Crizanlizumab Infusion in Patients (Pts) with
Sickle Cell Disease (SCD): A Systematic Evaluation of Post-Marketing
(PM) Reports. Blood. 2021 Nov 23;138(Supplement 1):3112.